InvestorsHub Logo
Followers 48
Posts 5518
Boards Moderated 0
Alias Born 09/04/2009

Re: None

Wednesday, 11/03/2021 3:20:02 PM

Wednesday, November 03, 2021 3:20:02 PM

Post# of 426480
Amarin's European launch 'going extremely well,' says Piper Sandler
Piper Sandler analyst Yasmeen Rahimi keeps an Overweight rating on Amarin with a $19 price target following the company's Q3 results. The European launch of Vascepa is "going extremely well" with 10 dossiers filed ahead of the end of 2021, Rahimi tells investors in a research note. Vascepa maintained its 83% hold on the market, and should see increased uptake with new methods to drive exposure and adoption, says the analyst. Rahimi remains confident in Amarin's execution for the Vascepa launch and uptake.

https://theflyonthewall.com/content_index.php?symbol=amrn&days_back=365&table=none
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News